Immune Pharmaceuticals applies a personalized approach to treatment and developing novel antibody therapeutics.
Business Model:
Revenue: $0
Employees: 11-50
Address:
City: New York
State: New York
Zip:
Country: United States
Immune Pharmaceuticals Inc. (NASDAQ OMX First North Premier: IMNP; OTCQX: IMNP,) applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company’s lead product candidate, Bertilimumab, is entering Phase II clinical studies for moderate-to-severe ulcerative colitis and bullous pemphigoid, with additional studies planned for Crohn’s disease and severe asthma.
Contact Phone:
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
1/10/2003
Ticker Symbol:
IMNP
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2016 | Post-IPO Equity | $11M | 7/2015 | Post-IPO Equity | $12M | 10/2017 | Post-IPO Equity | $18M | 7/2015 | Post-IPO Debt | $9.5M | 3/2014 | Post-IPO Equity | $11.7M |
---|
Announced Date | Name | Price |
---|---|---|
11/2012 | EpiCept Corporation |
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|